AKR1B1 and neuropathy: DXT and PGB, again in monotherapy, were compared, also recently, against a combination of either one with epalrestat (an aldose reductase inhibitor approved in some countries for the improvement of subjective neuropathy symptoms associated with diabetic peripheral neuropathy) [30].